Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
56,078,244
-
Number of holders
-
57
-
Total 13F shares, excl. options
-
21,487,475
-
Shares change
-
-7,770
-
Total reported value, excl. options
-
$36,340,473
-
Value change
-
-$284,945
-
Put/Call ratio
-
96%
-
Number of buys
-
18
-
Number of sells
-
30
-
Price
-
$1.69
Institutional Holders of Black Diamond Therapeutics, Inc. - Common Stock (BDTX) as of Q3 2022
As of 30 Sep 2022 Black Diamond Therapeutics, Inc. - Common Stock (BDTX) had 57 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 21,487,475 shares of stock of the company.
Largest 10 holders included Bellevue Group AG, NEA Management Company, LLC, RA CAPITAL MANAGEMENT, L.P., BOXER CAPITAL, LLC, Artal Group S.A., BlackRock Inc., K2 PRINCIPAL FUND, L.P., VANGUARD GROUP INC, Newtyn Management, LLC, and MILLENNIUM MANAGEMENT LLC.
This table shows 57 institutional shareholders of the security as of 30 Sep 2022.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.